<p><P>Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating busine
Leading Pharmaceutical Innovation
โ Scribed by Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer
- Publisher
- Springer International Publishing
- Year
- 2018
- Tongue
- English
- Leaves
- 189
- Edition
- 3rd ed.
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.
โฆ Table of Contents
Front Matter ....Pages i-xv
Innovation: Key to Success in the Pharmaceutical Industry (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 1-16
The Industry Challenge: Who Would Want to Be in This Business? (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 17-39
The Science and Technology Challenge: How to Find New Drugs (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 41-61
The Pipeline Challenge: How to Organize Innovation (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 63-78
The Make-or-Buy Challenge: How to In- and Outsource Innovation (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 79-110
The Open Innovation Challenge: How to Partner for Innovation (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 111-133
The Internationalization Challenge: Where to Access Innovation (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 135-153
Future Directions and Trends (Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer)....Pages 155-163
Back Matter ....Pages 165-179
โฆ Subjects
Business and Management; Innovation/Technology Management; Pharmaceutical Sciences/Technology; Pharmacoeconomics and Health Outcomes; Pharmacy; Health Care Management; Health Economics
๐ SIMILAR VOLUMES
<p><P>Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating busine
<p>We need a bold new brand of teacher leadership that will create opportunities for teachers to practice, share, and grow their knowledge and expertise.<br /> <br /> This book is about "teacherpreneurs"โhighly accomplished classroom teachers who blur the lines of distinction between those who teach
<p><span>We need a bold new brand of teacher leadership that will create opportunities for teachers to practice, share, and grow their knowledge and expertise.<br> <br> This book is about "teacherpreneurs"โhighly accomplished classroom teachers who blur the lines of distinction between those who tea
As the scope of available drug therapies expands, spending on prescription drugs has become the fastest-growing category of total spending on health care in the United States. Recently, that growth has slowed and that slowdown reflects changes in both the supply and demand for prescription drugs. Th